Tag: Zydus Therapeutics
Zydus Therapeutics announces positive phase 2b/3 results for Saroglitazar in primary...
EPICS-III trial met primary and key secondary endpoints, with Saroglitazar demonstrating significant efficacy, good tolerability, and paving the way for a planned U.S. regulatory submission in early 2026